Page 7,195«..1020..7,1947,1957,1967,197..7,2007,210..»

NPH diagnosis in San Tan Valley man returns him to normal life

Posted: Published on January 31st, 2012

Surgery to implant a shunt into a 75-year-old San Tan Valley man's brain has returned him to a nearly normal life years after he was diagnosed with Parkinson's disease and began suffering from bladder incontinence and dementia.  Edwin "Ed" Stall had been diagnosed with Parkinson's disease-like symptoms in 2007 at the age of 71. It was hard for him to walk and his balance was off. An MRI showed "nothing alarming," Stall said. "I always felt a sensation like I was falling forward when I was walking," he said. After falling a few times, the doctor tried to correct Edwin's gait, or his stance, as he walked. "He's always walked faster than me, because he's taller," his wife of 54 years said. "Then I started walking faster than he did." Over the next three years, Stall and his wife, Betty continued to seek answers to his medical problems to no avail. Slowly, he stopped being able to do work around the house or play a round of golf, he said. He was unable to walk down the street to a friend's house and instead had to have Betty drive the car. Eventually bladder incontinence made it nearly impossible to leave … Continue reading →

Posted in Parkinson's Treatment | Comments Off on NPH diagnosis in San Tan Valley man returns him to normal life

ACT Announces Aberdeen Royal Infirmary in Scotland as Additional Site for Phase 1/2 Clinical Trial Using hESC-Derived …

Posted: Published on January 31st, 2012

MARLBOROUGH, Mass.--(BUSINESS WIRE)-- Advanced Cell Technology, Inc. (“ACT”; OTCBB: ACTC), a leader in the field of regenerative medicine, announced today that the Aberdeen Royal Infirmary, the largest of the Grampian University Hospitals in Scotland, has been confirmed as a site for its Phase 1/2 human clinical trial for Stargardt’s Macular Dystrophy (SMD) using retinal pigment epithelial (RPE) cells derived from human embryonic stem cells (hESCs). The Phase 1/2 trial is a prospective, open-label study designed to determine the safety and tolerability of the RPE cells following sub-retinal transplantation into patients with SMD. “A leading medical institution in the United Kingdom, Aberdeen Royal Infirmary is an ideal partner for our European clinical trial for SMD,” said Gary Rabin, chairman and CEO of ACT. “Moreover, we are particularly pleased that the lead investigator is Dr. Noemi Lois, a leading expert in SMD. We continue to forge ties with some of the best eye surgeons and hospitals in the world and work towards bringing this cutting-edge therapy closer to fruition. Our preliminary results to date keep us optimistic that we are on the right path both in terms of our science and the clinical team we are working with, particularly eye surgeons such as Dr. … Continue reading →

Posted in Mesenchymal Stem Cells | Comments Off on ACT Announces Aberdeen Royal Infirmary in Scotland as Additional Site for Phase 1/2 Clinical Trial Using hESC-Derived …

'Personalized medicine' gets $67.5M research boost

Posted: Published on January 31st, 2012

The federal government is pledging up to $67.5 million for research into "personalized medicine," which tailors treatment to a patient's genetics and environment. The funds will flow through Genome Canada, the Cancer Stem Cell Consortium and the Canadian Institutes of Health Research, the federal government's health research agency. Federal Health Minister Leona Aglukkaq and Minister of State for Science Gary Goodyear made the announcement at the University of Ottawa's health campus Tuesday. The field of personalized medicine is touted as having the potential to transform the way patients are treated. It looks at the genetic makeup of a person, the patient's environment and the exact course of a particular disease so that an appropriate and effective treatment can be tailored for that individual. The idea is to move from a one-size-fits-all approach to one that is designed for a specific person and relies on the genetic signatures, or biomarkers, of both the patient and the disease. Proponents of personalized medicine say it is likely to change the way drugs are developed, how medicines are prescribed and generally how illnesses are managed. They say it will shift the focus in health care from reaction to prevention, improve health outcomes, make drugs … Continue reading →

Posted in Mesenchymal Stem Cells | Comments Off on 'Personalized medicine' gets $67.5M research boost

Damnit I’m A Doctor Not A TSA Agent (Brainstorm Ep43) – Video

Posted: Published on January 31st, 2012

30-01-2012 09:19 Website qdragon.info Shirts and Stuff http://www.zazzle.com My twitter twitter.com Like Brainstorm on Facebook http://www.facebook.com Technology News tinyurl.com Medical News tinyurl.com Biotechnology News tinyurl.com Hosted by http://www.youtube.com Contributors http://www.youtube.com http://www.youtube.com RNA Video http://www.youtube.com See more here: Damnit I'm A Doctor Not A TSA Agent (Brainstorm Ep43) - Video … Continue reading →

Comments Off on Damnit I’m A Doctor Not A TSA Agent (Brainstorm Ep43) – Video

Genetic Technologies Posts $1.6M in Revenues in Q2

Posted: Published on January 31st, 2012

Saladax Biomedical said today that President and CEO Edward Erickson has resigned due to personal and family reasons, and that he will be replaced by Kevin Harter on an interim basis. Erickson will remain a member of the company's board of directors. Harter is a co-founder and senior VP of the Life Sciences Greenhouse, and he has served as executive chairman at Saladax. Helicos Biosciences has elected Bruce Ginsberg to its board of directors to review certain financing matters. Ginsberg is president and CEO of MooBella, a food service provider, and a member of the board of directors of Mac-Gray. Life Technologies VP of Research and Development Manohar Furtado has been appointed to serve as an advisor on the National Biodefense Science Board, a federal advisory committee for the Department of Health and Human Services. The board provides advice on bioterrorism and other public health emergencies. Furtado was appointed to serve a four-year term on the board. Kevin Jarrell, CEO of Modular Genetics, also will continue to serve on the board. Here is the original post: Genetic Technologies Posts $1.6M in Revenues in Q2 … Continue reading →

Comments Off on Genetic Technologies Posts $1.6M in Revenues in Q2

Skin cells turned into neural precusors, bypassing stem-cell stage

Posted: Published on January 31st, 2012

ScienceDaily (Jan. 30, 2012) — Mouse skin cells can be converted directly into cells that become the three main parts of the nervous system, according to researchers at the Stanford University School of Medicine. The finding is an extension of a previous study by the same group showing that mouse and human skin cells can be directly converted into functional neurons. The multiple successes of the direct conversion method could refute the idea that pluripotency (a term that describes the ability of stem cells to become nearly any cell in the body) is necessary for a cell to transform from one cell type to another. Together, the results raise the possibility that embryonic stem cell research and another technique called "induced pluripotency" could be supplanted by a more direct way of generating specific types of cells for therapy or research. This new study, published online Jan. 30 in the Proceedings of the National Academy of Sciences, is a substantial advance over the previous paper in that it transforms the skin cells into neural precursor cells, as opposed to neurons. While neural precursor cells can differentiate into neurons, they can also become the two other main cell types in the nervous … Continue reading →

Comments Off on Skin cells turned into neural precusors, bypassing stem-cell stage

Stem-cell agency faces budget dilemma

Posted: Published on January 31st, 2012

Halfway through its initial ten-year mandate, the California Institute for Regenerative Medicine (CIRM) in San Francisco is confronting a topic familiar to anyone at middle age: its own mortality. The publicly funded institute, one of the world’s largest supporters of stem-cell research, was born from a state referendum in 2004. Endorsements from celebrities such as then-state governor Arnold Schwarzenegger and the late actor Christopher Reeve, who had been paralysed by a spinal injury, helped to garner voter support for a public bond to underwrite the institute. But with half of the US$3 billion that it received from the state now spent and the rest expected to run out by 2021, CIRM is now actively planning for a future that may not include any further state support. “It would be premature to even consider another bond measure at this time,” wrote Jonathan Thomas, CIRM’s chairman, in a draft of a transition plan requested by the state legislature. Thomas outlined the plan on 24 January at a public hearing held in San Francisco by the US Institute of Medicine, which CIRM has asked to review its operations. Given that California is facing severe budget shortfalls, several billion dollars more for stem-cell science may … Continue reading →

Comments Off on Stem-cell agency faces budget dilemma

ADDING MULTIMEDIA FDA Approves KALYDECO™ (ivacaftor), the First Medicine to Treat the Underlying Cause of Cystic …

Posted: Published on January 31st, 2012

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX - News) announced today that the U.S. Food and Drug Administration (FDA) has approved KALYDECOTM (ivacaftor), the first medicine to treat the underlying cause of cystic fibrosis (CF), a rare, genetic disease. KALYDECO (kuh-LYE-deh-koh) is approved for people with CF ages 6 and older who have at least one copy of the G551D mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Approximately 1,200 people in the United States, or 4 percent of those with CF, are believed to have this mutation. KALYDECO was granted approval in approximately three months, making it one of the fastest FDA approvals ever and marking the second approval of a new medicine from Vertex in less than a year. The company has established a financial assistance and patient support program to help get KALYDECO to eligible patients for whom it is prescribed. KALYDECO was discovered as part of a collaboration with Cystic Fibrosis Foundation Therapeutics, Inc., the nonprofit drug discovery and development affiliate of the Cystic Fibrosis Foundation. Vertex is ready to support the introduction of KALYDECO and will begin shipping it to pharmacies in the United States this week. The company will host a … Continue reading →

Posted in Cell Medicine | Comments Off on ADDING MULTIMEDIA FDA Approves KALYDECO™ (ivacaftor), the First Medicine to Treat the Underlying Cause of Cystic …

ATCC SDO Releases Ground-Breaking Standard for Human Cell Lines

Posted: Published on January 31st, 2012

MANASSAS, Va.--(BUSINESS WIRE)-- The ATCC® Standards Development Organization (ATCC SDO), an entity of ATCC, has published its second voluntary consensus standard, ASN-0002: “Authentication of Human Cell Lines: Standardization of STR Profiling.” This consensus standard is expected to have broad impact across basic cell research, drug discovery, and translational medicine. This approved American National Standard represents a major step forward in correcting the long standing problem of cell line misidentification. The standard’s intent is to delineate a standardized, universally applicable method for authenticating new and established human cell lines and human primary tissue used in research. A living document, the standard will be subject to revisions over time to reflect changes in the field and new methodologies. “This new standard is one example of our commitment to the program mission for the ATCC SDO---to develop and publish stakeholder-proposed, industry-relevant standards for biomaterials and related processes,” said Raymond Cypess, DVM, PhD, Chief Executive Officer for ATCC. “We are creating and maintaining biological standards that protect public interests,” said Dr. Cypess, “and we endeavor to ensure that government, regulatory agencies, industry and academia have the tools and resources to ensure the importance of properly authenticated material for biological research and product development.” Human cell … Continue reading →

Posted in Cell Medicine | Comments Off on ATCC SDO Releases Ground-Breaking Standard for Human Cell Lines

Biomerica Launches New Patented Test to Identify Individuals at Risk of Developing Severe Side Effects From Thiopurine …

Posted: Published on January 31st, 2012

IRVINE, CA--(Marketwire -01/31/12)- Biomerica, Inc. (OTC.BB: BMRA.OB - News) announced that it has launched a new patented Thiopurine methyltransferase (TPMT) test to detect patients who are at risk of developing severe or fatal side effects if treated with the class of thiopurine drugs that includes azathioprine, mercaptopurine, and thioguanine. Thiopurine drugs suppress the immune system and are used in the treatment of a wide range of diseases, such as inflammatory bowel disease, leukemia and lymphoma, autoimmune diseases and skin disorders such as psoriasis and severe eczema. They are also used to treat organ transplant patients. The most commonly used thiopurine drug is called azathioprine. It is estimated that one in every 300 people lacks TPMT, which is an enzyme that helps remove thiopurine drugs from the body when they are present. Individuals who lack the TPMT enzyme can become severely or fatally ill if treated with normal doses of thiopurine drugs because toxic levels of the drug accumulate. "Currently the two main U.S. reference labs offering TMPT testing charge over $200 per sample. We expect that our test will allow any lab or hospital to lower what they charge for TPMT testing to less than $120 per sample, a 40% … Continue reading →

Posted in Drug Side Effects | Comments Off on Biomerica Launches New Patented Test to Identify Individuals at Risk of Developing Severe Side Effects From Thiopurine …

Page 7,195«..1020..7,1947,1957,1967,197..7,2007,210..»